H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)

August 10, 2026 6:40 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $220.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "With ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found